Clinical Trial Update: APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating APG-2575 in combination regimens for relapsed or refractory multiple myeloma and amyloidosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyloidosis
• Multiple Myeloma

Drugs mentioned

• APG-2575

Snippet

Sponsor: Ascentage Pharma Group Inc. | Conditions: Multiple Myeloma, Amyloidosis | Phase 1, Phase 2 | Status: UNKNOWN